CD274 and cancer: This suggested that in cases showing low expression, other immune inhibitory pathways may be more important, leading to the design of antibodies targeting ICI other than CTLA-4 and PD-1/PD-L1, that are either overexpressed in specific types of tumors and/or involved in downmodulating anti-cancer immunity mediated by T cells, NK and myeloid cells [40,151].